120 related articles for article (PubMed ID: 38367494)
21. Evaluation of Novel Prostate-Specific Membrane Antigen-Targeted Near-Infrared Imaging Agent for Fluorescence-Guided Surgery of Prostate Cancer.
Kularatne SA; Thomas M; Myers CH; Gagare P; Kanduluru AK; Crian CJ; Cichocki BN
Clin Cancer Res; 2019 Jan; 25(1):177-187. PubMed ID: 30201762
[TBL] [Abstract][Full Text] [Related]
22. Novel Gastrin-Releasing Peptide Receptor Targeted Near-Infrared Fluorescence Dye for Image-Guided Surgery of Prostate Cancer.
Pagoto A; Garello F; Marini GM; Tripepi M; Arena F; Bardini P; Stefania R; Lanzardo S; Valbusa G; Porpiglia F; Manfredi M; Aime S; Terreno E
Mol Imaging Biol; 2020 Feb; 22(1):85-93. PubMed ID: 31025163
[TBL] [Abstract][Full Text] [Related]
23. Synthesis of IR-780 dye-conjugated abiraterone for prostate cancer imaging and therapy.
Yi X; Zhang J; Yan F; Lu Z; Huang J; Pan C; Yuan J; Zheng W; Zhang K; Wei D; He W; Yuan J
Int J Oncol; 2016 Nov; 49(5):1911-1920. PubMed ID: 27633959
[TBL] [Abstract][Full Text] [Related]
24. Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer.
Moi D; Bonanni D; Belluti S; Linciano P; Citarella A; Franchini S; Sorbi C; Imbriano C; Pinzi L; Rastelli G
Eur J Med Chem; 2023 Nov; 260():115730. PubMed ID: 37633202
[TBL] [Abstract][Full Text] [Related]
25. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
[TBL] [Abstract][Full Text] [Related]
26. Expression of oestrogen receptor-alpha and oestrogen receptor-beta in prostate cancer.
Yang GS; Wang Y; Wang P; Chen ZD
Chin Med J (Engl); 2007 Sep; 120(18):1611-5. PubMed ID: 17908481
[TBL] [Abstract][Full Text] [Related]
27. Near-Infrared Fluorescent Probe with Remarkable Large Stokes Shift and Favorable Water Solubility for Real-Time Tracking Leucine Aminopeptidase in Living Cells and In Vivo.
Zhang W; Liu F; Zhang C; Luo JG; Luo J; Yu W; Kong L
Anal Chem; 2017 Nov; 89(22):12319-12326. PubMed ID: 29048879
[TBL] [Abstract][Full Text] [Related]
28. The role of Eralpha and ERbeta in the prostate: insights from genetic models and isoform-selective ligands.
McPherson SJ; Ellem SJ; Patchev V; Fritzemeier KH; Risbridger GP
Ernst Schering Found Symp Proc; 2006; (1):131-47. PubMed ID: 17824175
[TBL] [Abstract][Full Text] [Related]
29. An ALP-activatable and mitochondria-targeted probe for prostate cancer-specific bimodal imaging and aggregation-enhanced photothermal therapy.
Yao D; Yang S; Wang Y; Bian K; Yang W; Wang D; Zhang B
Nanoscale; 2019 Mar; 11(13):6307-6314. PubMed ID: 30882834
[TBL] [Abstract][Full Text] [Related]
30. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
31. 17β-Estradiol regulates oxidative stress in prostate cancer cell lines according to ERalpha/ERbeta ratio.
Miró AM; Sastre-Serra J; Pons DG; Valle A; Roca P; Oliver J
J Steroid Biochem Mol Biol; 2011 Feb; 123(3-5):133-9. PubMed ID: 21172438
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of four affibody-based near-infrared fluorescent probes for optical imaging of epidermal growth factor receptor positive tumors.
Qi S; Miao Z; Liu H; Xu Y; Feng Y; Cheng Z
Bioconjug Chem; 2012 Jun; 23(6):1149-56. PubMed ID: 22621238
[TBL] [Abstract][Full Text] [Related]
33. Development of targeted near-infrared imaging agents for prostate cancer.
Wang X; Huang SS; Heston WD; Guo H; Wang BC; Basilion JP
Mol Cancer Ther; 2014 Nov; 13(11):2595-606. PubMed ID: 25239933
[TBL] [Abstract][Full Text] [Related]
34. 3,3'-Diindolylmethane, but not indole-3-carbinol, inhibits histone deacetylase activity in prostate cancer cells.
Beaver LM; Yu TW; Sokolowski EI; Williams DE; Dashwood RH; Ho E
Toxicol Appl Pharmacol; 2012 Sep; 263(3):345-51. PubMed ID: 22800507
[TBL] [Abstract][Full Text] [Related]
35. Activation of estrogen receptor beta (ERβ) regulates the expression of N-cadherin, E-cadherin and β-catenin in androgen-independent prostate cancer cells.
Silva RS; Lombardi APG; de Souza DS; Vicente CM; Porto CS
Int J Biochem Cell Biol; 2018 Mar; 96():40-50. PubMed ID: 29341930
[TBL] [Abstract][Full Text] [Related]
36. Fast clearing RGD-based near-infrared fluorescent probes for in vivo tumor diagnosis.
Cao J; Wan S; Tian J; Li S; Deng D; Qian Z; Gu Y
Contrast Media Mol Imaging; 2012; 7(4):390-402. PubMed ID: 22649045
[TBL] [Abstract][Full Text] [Related]
37. The role of histone deacetylases in prostate cancer.
Abbas A; Gupta S
Epigenetics; 2008 Nov; 3(6):300-9. PubMed ID: 19029799
[TBL] [Abstract][Full Text] [Related]
38. Expression and regulation of the estrogen receptors in PC-3 human prostate cancer cells.
Pisolato R; Lombardi AP; Vicente CM; Lucas TF; Lazari MF; Porto CS
Steroids; 2016 Mar; 107():74-86. PubMed ID: 26742628
[TBL] [Abstract][Full Text] [Related]
39. A Reactivity-Tunable Self-Immolative Design Enables Histone Deacetylase-Targeted Imaging and Prodrug Activation.
Liu F; Ding X; Xu X; Wang F; Chu X; Jiang JH
Angew Chem Int Ed Engl; 2022 Nov; 61(47):e202203243. PubMed ID: 36070285
[TBL] [Abstract][Full Text] [Related]
40. Estrogen receptors localization and signaling pathways in DU-145 human prostate cancer cells.
Souza DS; Lombardi APG; Vicente CM; Lucas TFG; Erustes AG; Pereira GJS; Porto CS
Mol Cell Endocrinol; 2019 Mar; 483():11-23. PubMed ID: 30660702
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
